Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antonio Conti is active.

Publication


Featured researches published by Antonio Conti.


Journal of Neurotrauma | 2004

Proteome Study of Human Cerebrospinal Fluid following Traumatic Brain Injury Indicates Fibrin(ogen) Degradation Products as Trauma-Associated Markers

Antonio Conti; Yovan Sanchez-Ruiz; Angela Bachi; Luigi Beretta; Elisabetta Grandi; Massimiliano Beltramo; Massimo Alessio

Traumatic brain injury (TBI), like other central nervous system pathologies, causes changes in the composition of cerebrospinal fluid (CSF). Consequently analysis of the CSF components is important to better understand the pathological processes involved in such diseases. The aim of this work was to identify specific markers of severe TBI. Proteomic analysis including two-dimensional gel electrophoresis combined with mass spectrometry analysis was used to compare the CSF protein profile of severe TBI patients and controls. Proteins (alpha 1 antitrypsin, haptoglobin 1 alpha1, alpha2, and beta) belonging to the acute phase response showed an increased expression in severe TBI patients. Two other proteins, identified as proteolytic degradation products of the carboxyl-terminal portion of the fibrinogen beta, were present only in TBI patients. The presence of these markers could correlate with a post-traumatic local increase in fibrinolysis as well as to an inflammatory event following CNS tissue injury.


Journal of Clinical Investigation | 2005

HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.

Cristina Scielzo; Paolo Ghia; Antonio Conti; Angela Bachi; Giuseppe Guida; Massimo Geuna; Massimo Alessio; Federico Caligaris-Cappio

We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgV(H) mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HS1). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed that patients with predominately phosphorylated HS1 experience a significantly shorter median survival time. As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement. Normal mature B cells stimulated by anti-IgM shifted the non- or less-phosphorylated form of HS1 toward the more phosphorylated form. Naive B cells showed both HS1 forms while memory B cells expressed mainly the phosphorylated fraction. These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.


Journal of Leukocyte Biology | 2009

Src family kinases are necessary for cell migration induced by extracellular HMGB1

Roberta Palumbo; Francesco De Marchis; Tobias Pusterla; Antonio Conti; Massimo Alessio; Marco Bianchi

HMGB1 is a nuclear protein that signals tissue damage, as it is released by cells dying traumatically or secreted by activated innate immunity cells. Extracellular HMGB1 elicits the migration to the site of tissue damage of several cell types, including inflammatory cells and stem cells. The identity of the signaling pathways activated by extracellular HMGB1 is not known completely: We reported previously that ERK and NF‐κB pathways are involved, and we report here that Src is also activated. The ablation of Src or inhibition with the kinase inhibitor PP2 blocks migration toward HMGB1. Src associates to and mediates the phosphorylation of FAK and the formation of focal adhesions.


Proteomics Clinical Applications | 2008

Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients

Antonio Conti; Sandro Iannaccone; Barbara Sferrazza; Lucia De Monte; Stefano F. Cappa; Diego Franciotta; Stefano Olivieri; Massimo Alessio

Amyotrophic lateral sclerosis (ALS) a fatal degenerative disease that selectively affects motor neurons, likely results from a complex interplay among oxidative injury, excitotoxic stimulation, protein aggregation and genetic factors. Ceruloplasmin (Cp) protein is a ferroxidase that oxidizes toxic ferrous iron to its nontoxic ferric form, protecting the central nervous system (CNS) from iron deposition. Cp is thus considered as one of the main systems dedicated to the protection of the CNS from oxidative stress damage. We investigated Cp protein behaviour in the cerebrospinal fluid (CSF) of ALS patients of recent onset. An increased expression of Cp was observed in ALS (n = 16) compared to two control groups (healthy subjects, n = 11 and peripheral neuropathy patients, n = 10). 2‐DE analysis revealed a differential expression of Cp isoforms in ALS patients compared to controls. ALS samples showed an increase in the relative abundance of more basic Cp forms, corresponding to the nonsialylated proteins. Despite the increase in protein expression, ferroxidase activity evaluated in the CSF of ALS patients was comparable to that of the controls, indicating a Cp functional impairment. Ceruloplasmin isoforms profile may be proposed as disease feature that could provide insight into the molecular mechanisms of ALS pathogenesis.


Biochimica et Biophysica Acta | 2014

Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients

Antonio Conti; Nilo Riva; Mariasabina Pesca; Sandro Iannaccone; Carlo Vittorio Cannistraci; Massimo Corbo; Stefano C. Previtali; Angelo Quattrini; Massimo Alessio

Amyotrophic lateral sclerosis (ALS) is a severe and fatal neurodegenerative disease of still unknown pathogenesis. Recent findings suggest that the skeletal muscle may play an active pathogenetic role. To investigate ALSs pathogenesis and to seek diagnostic markers, we analyzed skeletal muscle biopsies with the differential expression proteomic approach. We studied skeletal muscle biopsies from healthy controls (CN), sporadic ALS (sALS), motor neuropathies (MN) and myopathies (M). Pre-eminently among several differentially expressed proteins, Myosin binding protein H (MyBP-H) expression in ALS samples was anomalously high. MyBP-H is a component of the thick filaments of the skeletal muscle and has strong affinity for myosin, but its function is still unclear. High MyBP-H expression level was associated with abnormal expression of Rho kinase 2 (ROCK2), LIM domain kinase 1 (LIMK1) and cofilin2, that might affect the actin-myosin interaction. We propose that MyBP-H expression level serves, as a putative biomarker in the skeletal muscle, to discriminate ALS from motor neuropathies, and that it signals the onset of dysregulation in actin-myosin interaction; this in turn might contribute to the pathogenesis of ALS.


PLOS ONE | 2011

Secretion of novel SEL1L endogenous variants is promoted by ER stress/UPR via endosomes and shed vesicles in human cancer cells.

Monica Cattaneo; Lavinia Vittoria Lotti; Simone Martino; Massimo Alessio; Antonio Conti; Angela Bachi; Renato Mariani-Costantini; Ida Biunno

We describe here two novel endogenous variants of the human endoplasmic reticulum (ER) cargo receptor SEL1LA, designated p38 and p28. Biochemical and RNA interference studies in tumorigenic and non-tumorigenic cells indicate that p38 and p28 are N-terminal, ER-anchorless and more stable relative to the canonical transmembrane SEL1LA. P38 is expressed and constitutively secreted, with increase after ER stress, in the KMS11 myeloma line and in the breast cancer lines MCF7 and SKBr3, but not in the non-tumorigenic breast epithelial MCF10A line. P28 is detected only in the poorly differentiated SKBr3 cell line, where it is secreted after ER stress. Consistently with the presence of p38 and p28 in culture media, morphological studies of SKBr3 and KMS11 cells detect N-terminal SEL1L immunolabeling in secretory/degradative compartments and extracellularly-released membrane vesicles. Our findings suggest that the two new SEL1L variants are engaged in endosomal trafficking and secretion via vesicles, which could contribute to relieve ER stress in tumorigenic cells. P38 and p28 could therefore be relevant as diagnostic markers and/or therapeutic targets in cancer.


Experimental Biology and Medicine | 2008

An Integrated Strategy in Two-Dimensional Electrophoresis Analysis Able to Identify Discriminants Between Different Clinical Conditions

Linda Pattini; Saveria Mazzara; Antonio Conti; Sandro Iannaccone; Sergio Cerutti; Massimo Alessio

Two-dimensional gel electrophoresis (2DE) is an indispensable tool in proteomics for the analysis of protein expression in complex biological systems such as cells and tissues. However, the automatic extraction of information from gel images is still a challenging task. In this paper we propose a strategy that represents a computational procedure of support to the discrimination of different clinical conditions associated with the samples. The analyzed gel images were acquired within the framework of a study of peripheral neuropathies: twenty-four 2DE maps generated from cerebrospinal fluid (16 pathologic and 8 control subjects) were processed. Quantitative features were defined to describe each image and treated with a method of dimensionality reduction. The informativeness of the descriptors allowed us to see the gel of the data set as items in a three-dimensional space, segregating according to the clinical conditions. Moreover, information with prognostic value was obtained for a single outsider gel of a patient who was included in a clinical subgroup at the first diagnosis but whose disease progressed with clinical features belonging to a different clinical subgroup. The method developed may represent an effective tool of classification that can be used repeatedly to capture the essential impression from separation images.


Molecular Neurodegeneration | 2015

Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid.

Marco Barbariga; Flavio Curnis; Annapaola Andolfo; Alan Zanardi; Massimo Lazzaro; Antonio Conti; Giuseppe Magnani; Maria Antonietta Volontè; L. Ferrari; Giancarlo Comi; Angelo Corti; Massimo Alessio

BackgroundCeruloplasmin, a ferroxidase present in cerebrospinal fluid (CSF), plays a role in iron homeostasis protecting tissues from oxidative damage. Its reduced enzymatic activity was reported in Parkinson’s disease (PD) contributing to the pathological iron accumulation. We previously showed that ceruloplasmin is modified by oxidation in vivo, and, in addition, in vitro by deamidation of specific NGR-motifs that foster the gain of integrin-binding function. Here we investigated whether the loss of ceruloplasmin ferroxidase activity in the CSF of PD patients was accompanied by NGR-motifs deamidation and gain of function.ResultsWe have found that endogenous ceruloplasmin in the CSF of PD patients showed structural changes, deamidation of the 962NGR-motif which is usually hidden within the ceruloplasmin structure, and the gain of integrin-binding function. These effects occur owing to the presence of abnormal levels of hydrogen peroxide we detected in the CSF of PD patients. Interestingly, the pathological CSFs environment of PD patients promoted the same modifications in the exogenously added ceruloplasmin, which in turn resulted in loss of ferroxidase-activity and acquisition of integrin-binding properties.ConclusionsWe show that in pathological oxidative environment of PD-CSF the endogenous ceruloplasmin, in addition to loss-of-ferroxidase function, is modified as to gain integrin-binding function. These findings, beside the known role of ceruloplasmin in iron homeostasis, might have important pathogenic implications due to the potential triggering of signals mediated by the unusual integrin binding in cells of central nervous system. Furthermore, there are pharmacological implications because, based on data obtained in murine models, the administration of ceruloplasmin has been proposed as potential therapeutic treatment of PD, however, the observed CSFs pro-oxidant properties raise the possibility that in human the ceruloplasmin-based therapeutic approach might not be efficacious.


Embo Molecular Medicine | 2018

Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia

Alan Zanardi; Antonio Conti; Marco Cremonesi; Patrizia D'Adamo; Enrica Gilberti; Pietro Apostoli; Carlo Vittorio Cannistraci; Alberto Piperno; Samuel David; Massimo Alessio

Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration. Current therapies mainly based on iron chelation, partially control systemic iron deposition but are ineffective on neurodegeneration. We investigated the potential of ceruloplasmin replacement therapy in reducing the neurological pathology in the ceruloplasmin‐knockout (CpKO) mouse model of aceruloplasminemia. CpKO mice were intraperitoneal administered for 2 months with human ceruloplasmin that was able to enter the brain inducing replacement of the protein levels and rescue of ferroxidase activity. Ceruloplasmin‐treated mice showed amelioration of motor incoordination that was associated with diminished loss of Purkinje neurons and reduced brain iron deposition, in particular in the choroid plexus. Computational analysis showed that ceruloplasmin‐treated CpKO mice share a similar pattern with wild‐type animals, highlighting the efficacy of the therapy. These data suggest that enzyme replacement therapy may be a promising strategy for the treatment of aceruloplasminemia.


International Journal of Rheumatic Diseases | 2017

Rituximab hypersensitivity in IgG4-related disease: Successful desensitization in a patient with IgG4 rheumatoid factor

Emanuel Della-Torre; Antonio Conti; Alvise Berti; Mona Rita Yacoub; Massimo Alessio

Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor Emanuel DELLA-TORRE,* Antonio CONTI,* Alvise BERTI, Mona Rita YACOUB and Massimo ALESSIO Universit a Vita-Salute San Raffaele, School of Medicine, Unit of Medicine and Clinical immunology, and Proteome Biochemistry, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy

Collaboration


Dive into the Antonio Conti's collaboration.

Top Co-Authors

Avatar

Massimo Alessio

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Sandro Iannaccone

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Carlo Vittorio Cannistraci

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Angela Bachi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Stefano Olivieri

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Alan Zanardi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuseppe Magnani

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge